Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 9Completed 9Unknown 7Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 14Solid Tumor 12Mesothelioma 12Unspecified Adult Solid Tumor, Protocol Specific 9Solid Tumors 9Advanced Solid Tumors 8Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Retinoblastoma 5Advanced Solid Tumor 5Solid Tumor, Adult 4Lung Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pleural Effusion, Malignant 2Ovarian Neoplasms 2Neoplasms 2Metastatic Solid Tumors 2Melanoma 2Carcinoma, Renal Cell 2Carcinoma 2Anus Neoplasms 2Xerophthalmia 1Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor 1Triple Negative Breast Neoplasms 1Trachoma 1

Interventions

1-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Advanced Malignant Solid Tumors × Other solid neoplasm × Clear all
NCT00997360 2018-09-27

Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Withdrawn
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡